Inbound open innovation for pharmaceutical markets: a case study of an anti-diabetic drug in-licensing decision

被引:15
|
作者
Wu, Allan Ya-Huan [1 ]
Little, Victoria Janine [2 ]
Low, Brian [3 ]
机构
[1] Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand
[2] Univ Auckland, Dept Mkt, Auckland 1, New Zealand
[3] Monash Univ Malaysia, Dept Mkt, Kuala Lumpur, Malaysia
关键词
Decision-making; New product development; Pharmaceuticals industry; Technological innovation; Marketing management; Knowledge management; PRODUCT DEVELOPMENT; ABSORPTIVE-CAPACITY; FIRM RESOURCES; TECHNOLOGY; MODEL; VIEW; PERSPECTIVE; KNOWLEDGE; FRAMEWORK; BEHAVIOR;
D O I
10.1108/JBIM-10-2013-0236
中图分类号
F [经济];
学科分类号
02 ;
摘要
Purpose - This paper aims to increase understanding of how firms can more effectively identify valuable and profitable innovations in the pharmaceutical industry and to identify the issues and challenges posed by current managerial decision-making practices. Design/methodology/approach - A case study of a single project is presented: a drug in-licensing decision made by a team of three managers in a large Australian pharmaceutical firm. Using participant-observation, interviews and archival analysis, the authors followed the managers as they identified and evaluated 122 late-stage anti-diabetic drug variants for further development. Findings - The managers used decision heuristics to arrive at a short list of three drugs from a choice set of 122. While the process was ostensibly rational and systematic, there was evidence of data quality issues, misleading mental models and cognitive bias. The authors concluded a high probability of accepting a poor candidate or rejecting a stronger candidate (i.e. making Type I and II errors). Research limitations/implications - This paper focuses on initial market and technology evaluation stage only (i.e. not commercialization) and is a single case study design; therefore, care should be taken in generalizing to other decisions or other contexts. This paper highlights the need for further research integrating organizational decision-making and open innovation from a multi-disciplinary perspective. Practical/implications - This paper raises awareness of potential decision-making pitfalls and includes a detailed audit framework to support improved managerial decision processes and double rather than single loop learning. Social/implications - The findings support better decision-making and therefore supports higher quality drug selection and development, leading to improved population health outcomes. Originality/value - Multi-disciplinary, draws attention of marketing and new product development scholars to open innovation research. It adds to knowledge about open innovation practices at the project level. It also provides an extended model of market opportunity analysis for high technology markets.
引用
收藏
页码:205 / 218
页数:14
相关论文
共 37 条
  • [1] A Study on Drug-Drug Interaction of Esomeprazole and Anti-Diabetic Drugs
    Swamy, V. K. M.
    Setty, R. S.
    Shankaraiah, M. M.
    Jyothi, T. M.
    Rajendra, S., V
    [J]. JOURNAL OF YOUNG PHARMACISTS, 2010, 2 (04) : 424 - 427
  • [2] Stripping voltammetric quantification of the anti-diabetic drug glipizide in bulk form and pharmaceutical formulation
    Ghoneim, E. M.
    El-Attar, M. A.
    Hammam, E.
    Khashaba, P. Y.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 43 (04) : 1465 - 1469
  • [3] Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs
    Greco, Alessia
    Coperchini, Francesca
    Croce, Laura
    Magri, Flavia
    Teliti, Marsida
    Rotondi, Mario
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [4] Binding of acarbose, an anti-diabetic drug to lysozyme: a combined structural and thermodynamic study
    Dileep, K. V.
    Nithiyanandan, K.
    Remya, C.
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2018, 36 (13): : 3354 - 3361
  • [5] Fixed Drug Eruption Secondary to Four Anti-diabetic Medications: An Unusual Case of Polysensitivity
    Al Masri, Dana
    Fleifel, Mohamad
    Hirbli, Kamal
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [6] Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
    Kim, Sung-Ho
    Lee, Sung-Hack
    Yim, Hyeon-Joo
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2013, 36 (10) : 1185 - 1188
  • [7] Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
    Sung-Ho Kim
    Sung-Hack Lee
    Hyeon-Joo Yim
    [J]. Archives of Pharmacal Research, 2013, 36 : 1185 - 1188
  • [8] Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis' Anti-cancer Drug Glivec
    Ecks, Stefan
    [J]. BIOSOCIETIES, 2008, 3 (02) : 165 - 181
  • [9] Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis’ Anti-cancer Drug Glivec
    Stefan Ecks
    [J]. BioSocieties, 2008, 3 : 165 - 181
  • [10] Risk of pancreatitis in diabetic patients treated with anti-diabetic/hypoglycemic agents: A nested case control study
    Li, Lei
    Zhou, Ji
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 55 - 55